Zealand Pharma
Copenhagen · Founded 1998
About Zealand Pharma
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim. Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is marketed globally outside the US as Lyxumia:registered: by Sanofi and under regulatory review in the US. The license collaboration with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus:registered:) which is on track for regulatory submission in the US in December 2015 and in the European Union in Q1 2016. The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, ZP4207, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as several preclinical peptide therapeutics. The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand’s business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma
Company Facts
- Founded: 1998
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $1K – $10K
- Total funding: $1.6B
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2025)
- Ticker: cph:ZEAL
- Website: zealandpharma.com
- Phone: +45 88 77 36 00
Industries & Categories
Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/zealand-pharma-24975 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.